|
|
India's third biggest car maker Tata Motors is reportedly in talks with private equity funds to offload up to 25 percent of its stake in each of six unlisted group units to raise money to fund its $2.3 billion acquisition of Jaguar and Land Rover (JLR). According to sources close to the development, these units include Tata Daewoo Commercial Vehicle Co, HV Transmissions, Tata Motors Finance, Tata Technologies and Telco Construction Equipment. The sale of stakes, which will conclude by June 2009, is a part of the auto major's plan to raise Rs.3000 crore to fund the JLR deal. […]
Birmingham stockbroker Arden Partners is staying in touch with the Indian financial services company with which it has been discussing a possible bid since the early summer. The talks finally ended on Wednesday and Arden’s share price nearly halved to 43p on the news. It held steady at that level yesterday. Arden has strong contacts in India and has brought five Indian companies to the British stock market. The largest, Hardy Oil & Gas, is now in the FTSE 250 index. Arden was approached by three Indian financial companies after negotiations with Cenkos Securities ended in May. […]
World Bank's private sector financing arm International Finance Corporation (IFC) will be acquiring 46.50 lakh shares of Modern Dairies for Rs 27.90 crore. The dairy firm has entered into a 'Subscription Agreement' and a 'Shareholder Agreement' with IFC in this regard. As per the agreement, IFC would be subscribing up to 46.50 lakh shares at Rs 60 each, the Haryana-based firm said in a filing to the Bombay Stock Exchange. A meeting of the allotment committee of directors of Modern Dairies would be held on July 8, to allot the said number of shares, subject to the receipt of subscription amount from IFC. […]
Actis Biologics (India) is close to finalising a deal with private equity (PE) players to sell 15% stake. The company is in advanced stages of discussions with three foreign players to raise Rs 125 crore through issue of fresh shares, said Actis Biologics CEO Sanjeev Saxena. “The talks have taken longer time because of the global financial crisis. However, we hope to finalise a deal before the end of the year. The money raised will go towards the new plant to be built at Khopoli in Mumbai. The cost for the plant is estimated to be $9.5 million (approximately Rs 44 crore),”said Actis Biologics president PN Venugopalan. The remaining money would be utilised to meet the company’s working capital requirement in next 10 months till the plant is up and running and starts generating revenue. […]
ICICI Ventures, Larsen & Toubro and IL&FS are in the race to acquire a 51% stake in NTPC-BHEL Power Projects (NBPPL) — the 50:50 JV floated to manufacture power equipment and pitch for EPC (engineering, procurement & construction) jobs from the power sector. Indicating this, the Union minister of state for power, Jairam Ramesh, told ET: “The government intends to hand over the management control of NBPPL to a private strategic investor who will hold 51% stake and impart operational and managerial expertise to the venture. ICICI Ventures, Larsen & Toubro and IL&FS are in the race.” Mr Ramesh was in town to attend a boiler synchronisation ceremony of CESC’s Budge Unit-3 (250 mw) on Friday. This unit is slated to be commissioned in a record 30 months and is likely to start commercial generation by June 2009. […]
The race for U.K.-based software company Axon on Friday turned aggressive with HCL Technologies making a counter bid to Infosys’ bid by raising the offer by 8.3 per cent to seal the biggest overseas deal by an Indian firm in this space. HCL Technologies on Friday made an offer of 650 pence per share compared to Infosys’ offer of 600 pence announced late last month. This values Axon at 441.1 million pound ($810.8 million). After HCL’s offer, now Infosys will get a second chance to scale up its bid. In case Axon’s shareholders decide to go with the Shiv Nadar company’s offer, Infosys stands to be paid one per cent of the deal amount as inducement. […]
Fidelity Fund Management, part of Fidelity International, is planning investments in the life sciences segment. The company is looking at an investment of $200-$400 million by the end of this year through this foray. Speaking during the sidelines of ‘The ISB Healthcare and Pharma Conclave – Lens on emerging markets’ held in Hyderabad, Jasmin Patel, MD, said that this would be its first foray in the country focusing on pharmaceutical sector. ‘‘We are in close coordination with a few life sciences company and hope to close the deals by the end of this year,'' he said. The PE firm has invested about $40 million in a few companies which includes infrastructure and technology telecom company. […]
|
Post your messages.Please refrain from posting offensive messages. IndiaPE accepts no liability for the consequences of your reliance on these postings and messages.
|